ISSUE 1385
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Clobazam (Onfi – Lundbeck), an oral benzodiazepine, has been approved by the FDA for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years old. It has been available in Canada (Frisium) and other countries for years for treatment of anxiety and many types of epilepsy.
LENNOX-GASTAUT SYNDROME — LGS is a severe form of childhood epilepsy characterized by multiple types of seizures, developmental delays and impaired intellectual function. Most LGS patients require combinations of antiepileptic drugs to control their seizures. Drop attacks (atonic, tonic or myoclonic seizures resulting in sudden falls) occur in about half of patients with LGS. Most pediatric neurologists consider valproic acid (Depakene, and others) the first-line treatment, but only topiramate (Topamax, and others), lamotrigine (Lamictal, and others),
... more1. A Arzimanoglou et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009; 8:82.
2. Rufinamide (Banzel) for epilepsy. Med Lett Drugs Ther 2009; 51:18.
3. Drugs for epilepsy. Treat Guidel Med Lett 2008; 6:37.
6. Wholesale acquisition cost (WAC) of 60 10-mg tablets. Source: PricePointRx™. Reprinted with permission by FDB. All rights reserved. ©2012. http://www.firstdatabank.com/support/drugpricing-policy.aspx. Accessed February 24, 2012. Actual retail price may be higher.

Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1385b
Electronic, downloadable article - $45